Asia's drug development market opportunities include China's leadership, the dominance of small molecules and oncology, and increased clinical trial activity in South Korea and India. Japan focuses on multinational trials, with licensing preferred over M&A. O… For the full story, visit the source.
Business
Asia Drug Development Beyond China Strategic Intelligence Report 2026: Pharma R&D and Deal Trends in South Korea, Japan, and India
Asia's drug development market opportunities include China's leadership, the dominance of small molecules and oncology, and increased clinical trial activity in South Korea and India. Japan focuses on multinational trials, with licensing preferred over M&A. O…
By Research and Markets· GlobeNewswire· 2 days ago· 2 min read
This summary is sourced from GlobeNewswire. Read the full article at:GlobeNewswire